[CORRECTION] The Hot Corner: The Kings of Biotech are Back

Wednesday, March 25, 2026 **The previous Hot Corner email contained the incorrect day's post. Today's correct Hot Corner report is below. Apologies for the confusion.   Every day, we sift through the filings to spot where the real conviction lies – cutting through the noise to highlight the most meaningful insider moves.   📌 Celcuity $CELC — Baker Bros. Advisors increased its 13D stake from 17.11% to 19.99%.   The biotech-focused specialists continue to press their bet, adding on strength and pushing ownership close to 20%.    When the Baker Bros lean in like this, it's worth paying attention.   📌 ARS Pharmaceuticals $SPRY — Millennium Management increased its 13G stake from 3.21% to 5.40%. The multi-strategy fund crosses the key 5% threshold, building a meaningful position in the biotech name as shares continue to carve out a multi-year distribution range.   Here's The Hot Corner, with data from March 24, 2026: Click the table to enlarge it. 📌 Banc of California $BANC — Millennium Management increased its 13G stake from 1.14% to 5.00%. A notable addition in the regional bank space, with the fund stepping in as the group faces pressure, suggesting a longer-term view despite near-term weakness.   If you want this actionable trade ideas based on insider trading, join Hot Corner Insider risk-free. Jason Perz nearly tripled his portfolio in 2025 trading gold miners, silver producers, and base metals — before the crowd showed up.   Tomorrow, March 26 @ 2pm ET, he's breaking down exactly how he did it and what he's buying next.   Reserve your free seat here. Alfonso De Pablos | Director of Research, All Star Charts Stock Market Media emails are a financial publication of general circulation and only offers impersonal advice, not tailored to individual needs of a specific client or group. Any comments or statements made herein do not necessarily reflect those of Stock Market Media LLC or its affiliates (collectively, "Stock Market Media") and do not constitute buy or sell recommendations. Unless specifically indicated, this message is not an official confirmation of any transaction. The contents of any email communications to or from Stock Market Media may be monitored or reviewed at Stock Market Media's discretion. Stock Market Media accepts no responsibility for any loss or damage arising in any way from the use of this transmission and any attachments; it is the responsibility of the recipient to ensure that they are virus free. If you reply to this email, please note that we are a public investor and do not want any material non-public information. We do not agree to keep confidential any information you provide and do not agree to any restrictions on our trading activity, except pursuant to a written confidentiality agreement executed by Stock Market Media. Want to change how you receive these emails? You can manage your preferences here unsubscribe. © 2026 Stock Market Media 624 Broadway, Suite 405 San Diego, CA 92101